Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression

Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression is a phase 2, randomised interventional study registered as NCT07176182 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 236 participants, started 2026-03-20 and due to reach its primary completion in 2031-03-20. Interventions recorded: mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group; mFOLFOX regimen neoadjuvant therapy group. Conditions listed: Rectal Cancer Patients; Rectal Cancer Stage II; Rectal Cancer Stage III. Primary outcome: Tumor downstaging rate (to ypTNM stage 0-I). Colorectal eligibility wording from the registry: "Histopathologically confirmed rectal adenocarcinoma; all other histologic subtypes are excluded". Sites: China. No results are recorded here; the registry entry is the source.